ASCO issues new guidelines on treatment of metastatic prostate cancer

New guidelines on the management of metastatic, hormone-sensitive prostate cancer have just been released by the American Society for Clinical Oncology (ASCO), based primarily on data from the CHAARTED, STAMPEDE, and LATITUDE trial data. … READ MORE …

Should perineural invasion influence active surveillance and radiation treatment options?

Perineural invasion (PNI) is a risk factor detected on a biopsy in 15 to 38 percent of men with a prostate cancer diagnosis. … READ MORE …

Major US insurer to cover use of HIFU for treatment of radiorecurrent prostate cancer

According to a media release issued on March 18 by EDAP TMS, the US healthcare insurance firm CIGNA has agreed to cover the use of high-intensity focal ultrasound (HIFU) as a second-line, salvage therapy for men with radiorecurrent prostate cancer. … READ MORE …

A PSMA-based PET scan can change SRT decisions

The new PSMA-based PET scans provide a way to locate exactly where the cancer has spread to after an unsuccessful prostatectomy. … READ MORE …

What to do first for men with mCRPC

The currently “great unanswered” question in the management of advanced prostate cancer is the order of agents to be used in the treatment of men who are receiving first-line therapy for metastatic prostate cancer after it becomes castration-resistant. … READ MORE …

Improving survival among men with oligorecurrent prostate cancer?

A newly published article in the Journal of Clinical Oncology reports data from a small, randomized, multicenter, Phase II clinical trial comparing active monitoring to treatment of men with recurrent, asymptomatic, oligometastatic prostate cancer. … READ MORE …

Enzalutamide treatment and risk for seizures

The “Warnings and Precautions” section of the product prescribing information for enzalutamide (Xtandi) includes the following statement: … READ MORE …

Why is this debate still going on at all?

The question between different types of physician as to whether radiation therapy or surgery is “better” for the first-line, curative treatment of localized prostate cancer has now been debated (over and over) for more than 40 years. … READ MORE …

Understanding genetics, genomics, and their utility in prostate cancer

Our friends at UroToday have just published a perfectly lovely lecture on this topic given by Prof. Lenny Gomella at the recent annual meeting of the Large Urology Group Practice Association (LUGPA). … READ MORE …

Men initially diagnosed with de novo metastatic prostate cancer are living longer

A newly published study entitled “Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study” is important … but needs to be interpreted with a significant degree of caution. … READ MORE …

Personality and its impact on prostate cancer and its treatment

Your sitemaster is going to write this commentary with as much tact as he can muster but he is aware that this is going to be a very sensitive subject for some readers to deal with. … READ MORE …

A specific subset of men with a specific genetic variation respond to non-steroidal CYP17A1 inhibition

Just over a year ago, we reported on a paper by Hearn et al. that had shown that a specific inherited mutation in the HSD3B1 gene seemed to be associated with a more aggressive form of prostate cancer that was less responsive to treatment with androgen deprivation therapy (ADT). … READ MORE …

Germline genetics and different responses to different types of ADT

Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …

Patients’ understanding of the risks and benefits of first-line treatment

A newly published article in BJU International has (finally) proven something many prostate cancer educators and advocates have known for years: many patients have a very poor appreciation of the risks and benefits of their differing treatment options at the time they make decisions about first-line treatment for localized prostate cancer. … READ MORE …

Repeated treatment with radium-223 after a first treatment cycle

Radium-223 or Xofigo was first approved in 2013 as “an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.” That meant (and still means) one course of treatment with six cycles of radium-223. However, … READ MORE …